Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.76 |
| ▸ | LRRK2 | Q5S007 | 16/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.58 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.57 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.57 |
| ▸ | CLK1 | P49759 | 1/20 | 0.57 |
| ▸ | CLK2 | P49760 | 1/20 | 0.57 |
| ▸ | CLK3 | P49761 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22264283 | 0.94 | TTK (0.82) | TTKLRRK2JAK2 | |
| SCHEMBL22264356 | 0.93 | TTK (0.85) | TTKLRRK2DYRK1ADYRK3CSNK1E | |
| SCHEMBL22264391 | 0.93 | TTK (0.74) | TTKLRRK2DYRK1ADYRK3CSNK1E | |
| SCHEMBL22264397 | 0.91 | LRRK2 (0.72) | TTKLRRK2DYRK1ADYRK3CSNK1E | |
| SCHEMBL21738219 | 0.90 | TTK (0.69) | TTKLRRK2DYRK1ADYRK3CSNK1E | |
| SCHEMBL22280085 | 0.90 | TTK (0.71) | TTKLRRK2 | |
| SCHEMBL18018932 | 0.90 | LRRK2 (0.88) | TTKLRRK2DYRK1ADYRK3CSNK1E | |
| SCHEMBL21611018 | 0.89 | DYRK1A (0.66) | TTKLRRK2DYRK1ADYRK3CSNK1E | |
| SCHEMBL22264442 | 0.89 | TTK (0.68) | TTKLRRK2DYRK1ADYRK3CSNK1E | |
| SCHEMBL21638145 | 0.88 | DYRK1A (0.67) | TTKLRRK2DYRK1ADYRK3CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208412-B2 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-12-28 | — | — | US | claimed |
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2020-07-30 | — | — | US | claimed |
| US-11208412-B2 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-12-28 | — | — | US | disclosed |
| US-11208412-B2 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-12-28 | — | — | US | disclosed |
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2020-07-30 | — | — | US | disclosed |
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208412-B2 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease | LRRK2, WEE1, WEE2 | TTK 1047/4885LRRK2 1/4885DYRK1A 897/4885 |
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | LRRK2, WEE1, WEE2 | TTK 1047/4885LRRK2 1/4885DYRK1A 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.